牛牛AI助理已提取核心訊息
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 2,465 shares of common stock on February 28, 2024, according to a recent filing. The shares, valued at an aggregate market value of $26,129, were acquired by Watanabe on February 27, 2024, through the vesting of restricted stock directly from Arcutis Biotherapeutics. This transaction follows a period where no other sales were reported by Watanabe in the past three months.
Arcutis Biotherapeutics, Inc. officer Todd Franklin Watanabe is set to sell 2,465 shares of common stock on February 28, 2024, according to a recent filing. The shares, valued at an aggregate market value of $26,129, were acquired by Watanabe on February 27, 2024, through the vesting of restricted stock directly from Arcutis Biotherapeutics. This transaction follows a period where no other sales were reported by Watanabe in the past three months.
根據最近的一份文件，Arcutis Biotherapeutics, Inc.高管託德·富蘭克林·渡邊定於2024年2月28日出售2465股普通股。這些股票的總市值爲26,129美元，於2024年2月27日被渡邊通過直接從Arcutis Biotherapeutics授予限制性股票的方式收購。這筆交易是在渡邊在過去三個月中沒有報告其他銷售額之後進行的。
根據最近的一份文件，Arcutis Biotherapeutics, Inc.高管託德·富蘭克林·渡邊定於2024年2月28日出售2465股普通股。這些股票的總市值爲26,129美元，於2024年2月27日被渡邊通過直接從Arcutis Biotherapeutics授予限制性股票的方式收購。這筆交易是在渡邊在過去三個月中沒有報告其他銷售額之後進行的。
有用
沒用